Need Help?
Contact Us
Clinical Spotlight - From the desk of Craig Thompson MD and Keith Dawkins MD, Chief Medical Officers, Boston Scientific Clinical Spotlight - From the desk of Craig Thompson MD and Keith Dawkins MD, Chief Medical Officers, Boston Scientific

We are pleased to release the latest edition of the Clinical Spotlight highlighting two exciting BSC technologies: the SYNERGY Stent System and the Lotus Valve System. As your peers, it is our pleasure to share the scientific story behind SYNERGY providing you with insights into the pre-clinical data and our robust Investigator-Sponsored Research (ISR) program, updates on the EVOLVE Short DAPT study and a comprehensive video review from our principal investigators. This newsletter also showcases the Lotus Valve, with an update on the RESPRISE III study, commentary from the PIs, and the latest clinical data presentations from PCR London Valves 2015 and TCT 2015.

We truly hope this content resonates and has a positive impact for your clinical practice.

Craig A. Thompson, MD
Senior Vice President and Chief Medical Officer
Interventional Cardiology

Keith D. Dawkins, MD
Executive Vice President and Global Chief Medical Officer

SYNERGY Science Behind the Stent

Dr. Dean Kereiakes, principal investigator of EVOLVE II, details the SYNERGY Stent design, the need for bioabsorbable polymer technology, and the current clinical data.

Watch the videos

SYNERGY Investigator-Sponsored Research

The Role of Investigator-Sponsored Research in the SYNERGY Clinical Program

CMO Dr. Craig Thompson and Dr. de la Torre Hernandez comment on Investigator-Sponsored Research regarding SYNERGY. Also see results from Dr. de la Torre Hernandez’s OCT Healing Assessment of SYNERGY and review the current ISR Program for the SYNERGY Stent.

What is an ISR?

SYNERGY EVOLVE Short DAPT Begins Enrollment

Evaluation of reduced DAPT duration with next generation bioabsorbable polymer DES

As principal investigator of the recently approved EVOLVE Short DAPT trial, Dr. Mauri will be evaluating a novel, bioabsorbable polymer DES, SYNERGY, with 3 month DAPT in patients at high risk for bleeding.  Read Dr. Mauri’s EVOLVE Short DAPT announcement and view the EVOLVE Short DAPT Study Design.

Read Dr. Mauri's Announcement

SYNERGY Further Evidence for Early Healing

How does SYNERGY compare with other stents regarding endothelial cell coverage, endothelial cell function, and thrombogenicity?  Click here to see the pre-clinical data.

Review the data

Lotus REPRISE III Completes Enrollment

First US Head-to-Head Lotus Valve vs. CoreValve Study Update

REPRISE III PI’s Dr. Feldman and Dr. Reardon share insight on recent and upcoming milestones for the Lotus Valve. View the latest Lotus Valve clinical data presentations and review the REPRISE III Study Design.

View the latest data